BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33774805)

  • 1. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
    Zhang N; Gao Y; Zeng Z; Luo Y; Jiang X; Zhang J; Li J; Zhang J; Gong Y; Xie C
    Clin Transl Oncol; 2021 Sep; 23(9):1827-1837. PubMed ID: 33774805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
    Bridges KA; Toniatti C; Buser CA; Liu H; Buchholz TA; Meyn RE
    Oncotarget; 2014 Jul; 5(13):5076-86. PubMed ID: 24970803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study.
    Cui Y; Huang W; Du F; Yin X; Feng L; Li B
    Clin Transl Oncol; 2022 Aug; 24(8):1643-1656. PubMed ID: 35364771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
    Wang Z; Sun K; Xiao Y; Feng B; Mikule K; Ma X; Feng N; Vellano CP; Federico L; Marszalek JR; Mills GB; Hanke J; Ramaswamy S; Wang J
    Sci Rep; 2019 Feb; 9(1):1853. PubMed ID: 30755715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 7. Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.
    Hastak K; Bhutra S; Parry R; Ford JM
    Oncotarget; 2017 Apr; 8(16):26344-26355. PubMed ID: 28412751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
    Luo J; Dai X; Hu H; Chen J; Zhao L; Yang C; Sun J; Zhang L; Wang Q; Xu S; Xu Y; Liu N; Ying G; Wang P
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):721-737. PubMed ID: 31786739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 11. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer.
    Meng J; Peng J; Feng J; Maurer J; Li X; Li Y; Yao S; Chu R; Pan X; Li J; Zhang T; Liu L; Zhang Q; Yuan Z; Bu H; Song K; Kong B
    J Transl Med; 2021 Oct; 19(1):415. PubMed ID: 34620163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton and photon radiosensitization effects of niraparib, a PARP-1/-2 inhibitor, on human head and neck cancer cells.
    Wang L; Cao J; Wang X; Lin E; Wang Z; Li Y; Li Y; Chen M; Wang X; Jiang B; Zhang R; Sahoo N; Zhang X; Zhu XR; Myers JN; Frank SJ
    Head Neck; 2020 Sep; 42(9):2244-2256. PubMed ID: 32323895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
    Perez JM; Twigg CAI; Guan W; Thomas SN
    J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
    Parkes EE; Walker SM; Taggart LE; McCabe N; Knight LA; Wilkinson R; McCloskey KD; Buckley NE; Savage KI; Salto-Tellez M; McQuaid S; Harte MT; Mullan PB; Harkin DP; Kennedy RD
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity.
    Chen D; Barsoumian HB; Fischer G; Yang L; Verma V; Younes AI; Hu Y; Masropour F; Klein K; Vellano C; Marszalek J; Davies M; Cortez MA; Welsh J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
    Albert JM; Cao C; Kim KW; Willey CD; Geng L; Xiao D; Wang H; Sandler A; Johnson DH; Colevas AD; Low J; Rothenberg ML; Lu B
    Clin Cancer Res; 2007 May; 13(10):3033-42. PubMed ID: 17505006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer.
    Shen D; Luo J; Chen L; Ma W; Mao X; Zhang Y; Zheng J; Wang Y; Wan J; Wang S; Ouyang J; Yi H; Liu D; Huang W; Zhang W; Liu Z; McLeod HL; He Y
    Cancer Lett; 2022 Dec; 550():215919. PubMed ID: 36116741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation.
    Jonuscheit S; Jost T; Gajdošová F; Wrobel M; Hecht M; Fietkau R; Distel L
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34073147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor, Inhibition of Metastasis and Radiosensitizing Effects of Total Nutrition Formula on Lewis Tumor-Bearing Mice.
    Liu YM; Chan YL; Wu TH; Li TL; Hsia S; Chiu YH; Wu CJ
    Nutrients; 2019 Aug; 11(8):. PubMed ID: 31426614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.